Sysmex, the world leader in Haematology, in partnership with Transasia Bio-Medicals introduce the XT-1800i V & XT-2000i V (Veterinary mode), a fully automated Haematology analyzer for High Quality Animal Blood testing. This instrument will be highly beneficial to India’s growth in the Contract Clinical Research sector and Pharmaceutical R&D. A lot of CROs and Pharmaceutical companies in India are working on development of new Drugs both independently and in collaboration with certain MNCs. There are very strict regulatory norms both by Indian FDA as well as US FDA which needs to be followed. Animal testing is also mandatory to check the effectiveness of different compounds and their side effects. XT-1800i V & XT-2000i V Vet Analyzer offers superior diagnostics for animal blood analysis thereby ensuring high quality standards to support Clinical trials & drug discovery. The unique feature of XT-1800i V & XT-2000i V Vet Analyzer is its ability to “Analyze as many species as one can imagine” i.e. nearly unlimited species that can be defined by the user themselves. The use of principle of Advanced Fluorescence flowcytometry ensures Efficient Quality Control. It also ensures full traceability and recording of all data without any possibility of overwriting the original data, which is in compliance with U.S. FDA. XT-1800i V & XT-2000i V Vet Analyzer is a must for all veterinary universities, research labs, Veterinary Hospitals, Pharmaceutical Companies & Toxicological Labs involved in Clinical trials as it is Low maintenance and Robust analyzer. Also most of the Companies involved in Clinical trials work in partnership with companies operational at the global level and have work going on simultaneously at different centers. They need to compile data in real time which only Sysmex can offer by its online Quality Control of Sysmex Network Communication System (SNCS), which is an internet based online customer service which enables to maintain the total quality on Sysmex hematology analyzers. Above all the direct benefit to all will be a better health and access to a subsidised Healthcare.